Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to johnstevens77,Bhoddhisatva,scotia,Anonymous,Cornytiv34, for Donating to support the site

AstraZeneca PLC (AZN)

Share latest information on individual companies and hot news discussions. LSE Main Market companies only
Forum rules
No penny shares or promotional posts
idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#518065

Postby idpickering » July 29th, 2022, 7:19 am

H1 2022 results

H1 2022 Financial performance (growth numbers and commentary at CER)
‒ Total Revenue increased 48% to $22,161m, with growth coming from all disease areas and from the addition
of Alexion
‒ Total Revenue from Oncology increased 22%5
, including receipt of a milestone payment. Product Sales from
Oncology increased 18%. Total Revenue from R&I6
increased 3%, CVRM7
increased 19%8 and Rare
Disease increased 10%8
. Excluding a one-off historical pricing adjustment, Rare Disease increased 8%
‒ Core Gross Margin of 81%, with the second quarter benefitting from currency fluctuations, and phasing of
COVID-19 medicine contracts
‒ Core Operating Margin of 33%. Core Total Operating Expense increased 33%, reflecting the addition of
Alexion, and continued investment in new launches and the pipeline to build industry-leading mid-to-long
term growth
‒ Core EPS of $3.61, with the second quarter benefitting from a Core Tax Rate of 15%. The FY 2022
expectation for the Core Tax Rate remains 18-22%
‒ Interim dividend declared of $0.93 (76.4 pence, 9.49 SEK) per ordinary share, reflecting the Board’s intent
to increase to $2.90 in FY 2022, as announced at FY 2021
‒ FY 2022 Total Revenue guidance at CER increased due to an updated outlook for COVID-19 medicines and
continued strong performance of the overall business, enabling further investment in the pipeline. With an
expectation that Other Operating Income in H2 2022 will be similar to H1 2022, EPS guidance is unchanged.

The record date for the first interim dividend for 2022, payable on 12 September 2022, will be 12 August 2022.
The ex-dividend date will be 11 August 2022


https://www.astrazeneca.com/content/dam ... cement.pdf

RNS here; https://www.investegate.co.uk/astrazene ... 00111686U/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#518071

Postby idpickering » July 29th, 2022, 7:32 am

Chair succession.

AstraZeneca PLC today announced the appointment of Michel Demaré as the Chair-designate of the Board.

His appointment followed a robust succession planning process led by Philip Broadley in his capacity as senior independent Non-Executive Director.

As previously communicated, Leif Johansson, current Chair of the Board of AstraZeneca will be retiring at the conclusion of the Company's Annual General Meeting in April 2023. Michel's appointment will take effect immediately on Leif's retirement allowing for a managed handover period over the coming months.

Michel was appointed to the Board of AstraZeneca in September 2019 as an independent Non-Executive Director and is currently Chair of the Company's Remuneration Committee and member of the Audit Committee and the Nomination and Governance Committee. He is a Non-Executive Director of Vodafone Group Plc and Louis Dreyfus Int'l Holdings BV. He is also Chairman of IMD Business School and Chairman of Nomoko AG.

Leif Johansson, AstraZeneca Chair said: "I am delighted that Michel will succeed me following the 2023 AGM. He is an internationally respected leader with extensive experience in strategy, planning, execution, governance and corporate stewardship and a proven track record leading multinational companies, as well as experience of the pharmaceutical industry gained at Baxter and as a member of the AstraZeneca Board. I look forward to undertaking a comprehensive handover in the coming months and to seeing the continued development and success of AstraZeneca."

Michel Demaré, AstraZeneca Chair-designate said: "I could not be prouder to be named Chair-designate of the Board of AstraZeneca and am excited to have the opportunity to build on Leif's success as Chair and work with Pascal and members of the Board and Senior Executive Team when I take on my new role in 2023."


https://www.investegate.co.uk/astrazene ... 01051646U/

Ian.

77ss
Lemon Quarter
Posts: 1271
Joined: November 4th, 2016, 10:42 am
Has thanked: 233 times
Been thanked: 414 times

Re: AstraZeneca PLC (AZN)

#518102

Postby 77ss » July 29th, 2022, 9:31 am

idpickering wrote:H1 2022 results

H1 2022 Financial performance (growth numbers and commentary at CER)
‒ Total Revenue increased 48% to $22,161m, with growth coming from all disease areas and from the addition
of Alexion.....
......
‒ Interim dividend declared of $0.93 (76.4 pence, 9.49 SEK) per ordinary share, reflecting the Board’s intent
to increase to $2.90 in FY 2022, as announced at FY 2021
......
...
RNS here; https://www.investegate.co.uk/astrazene ... 00111686U/

Ian.


It has been an interesting week for me - and probably for others too. Results from ULVR, RIO, SGRO, DGE, CRDA and now AZN.

No surprises on the dividend front - although I hadn't realised that the £ had weakened so much - so AZN's £ interim is up by 17.9% over last year (3.33% in $ terms).

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#520653

Postby idpickering » August 8th, 2022, 7:29 am

Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer.

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

The approval by the Food and Drug Administration (FDA) was based on the results from the DESTINY-Breast04 Phase III trial. In the trial, Enhertu reduced the risk of disease progression or death by 50% versus physician's choice of chemotherapy in patients with HER2-low metastatic breast cancer with hormone receptor (HR)-positive disease or HR-negative disease (median progression-free survival [PFS] 9.9 versus 5.1 months; hazard ratio [HR] 0.50; 95% confidence interval [CI] 0.40-0.63; p<0.0001). A median overall survival (OS) of 23.4 months was seen in patients treated with Enhertu versus 16.8 months in those treated with chemotherapy, a 36% reduction in the risk of death (HR 0.64; 95% CI 0.49-0.84; p=0.001).


https://www.investegate.co.uk/astrazene ... 10052205V/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#521513

Postby idpickering » August 11th, 2022, 7:23 am

Acquisition of TeneoTwo completed.

AstraZeneca has completed the acquisition of TeneoTwo, Inc . (TeneoTwo) i , including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486 , currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.1 AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies.

Financial considerations

AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m. Under the terms of the agreement, AstraZeneca will make additional contingent R&D-related milestone payments of up to $805m and additional contingent commercial-related milestone payments of up to $360m to TeneoTwo's former equity holders.


https://www.investegate.co.uk/astrazene ... 00126383V/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#521831

Postby idpickering » August 12th, 2022, 8:19 am

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan ) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

The accelerated approval by the FDA was based on the results from the DESTINY-Lung02 Phase II trial. An interim efficacy analysis in a pre-specified patient cohort showed Enhertu (5.4mg/kg) demonstrated a confirmed ORR of 57.7% (n=52; 95% confidence interval [CI] 43.2-71.3), as assessed by blinded independent central review (BICR), in patients with previously treated unresectable or metastatic non-squamous HER2-mutant (HER2m) NSCLC. Complete responses (CR) were seen in 1.9% of patients and partial responses (PR) in 55.8% of patients with a median DoR of 8.7 months (95% CI 7.1-NE). Results from the DESTINY-Lung02 trial will be presented at an upcoming medical meeting.


https://www.investegate.co.uk/astrazene ... 00098362V/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#522501

Postby idpickering » August 15th, 2022, 7:19 am

Enhertu improved PFS in mBC in DESTINY-Breast02.

Positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician's choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1). The trial also met the key secondary endpoint of improved overall survival (OS).


https://www.investegate.co.uk/astrazene ... 00069389V/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#522759

Postby idpickering » August 16th, 2022, 7:07 am

Lynparza granted FDA priority review for PROpel.

AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).


https://www.investegate.co.uk/astrazene ... 00111475W/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#525226

Postby idpickering » August 25th, 2022, 4:07 pm

AZN put out these three announcements this morning;

Ultomiris approved in Japan for gMG.

https://www.investegate.co.uk/astrazene ... 10011480X/

Tagrisso approved in Japan for early lung cancer.

https://www.investegate.co.uk/astrazene ... 05001496X/

Lynparza approved in Japan for early breast cancer.

https://www.investegate.co.uk/astrazene ... 00031543X/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#526325

Postby idpickering » August 30th, 2022, 8:49 am

Farxiga shows CV mortality benefit across EF range.

https://www.investegate.co.uk/astrazene ... 01044513X/

Farxiga reduced risk of CV death or worsening HF.

https://www.investegate.co.uk/astrazene ... 00134512X/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#526398

Postby idpickering » August 30th, 2022, 1:49 pm

Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan.

https://www.investegate.co.uk/astrazene ... 00016154X/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#527531

Postby idpickering » September 5th, 2022, 7:39 am

Two announcements put out by AZN today thus far;

Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes.

https://www.investegate.co.uk/astrazene ... 05051910Y/

Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer.

https://www.investegate.co.uk/astrazene ... 00071907Y/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#529274

Postby idpickering » September 12th, 2022, 7:13 am

AstraZeneca looks to more than double new cancer drugs by 2030.

The UK drugmaker has added 7 new cancer medicines since 2014 after chief executive officer Pascal Soriot made a risky bet on an oncology pipeline to revive growth and ward off a hostile takeover from Pfizer. Now, with blockbuster treatments for malignancies in the lungs, ovaries and blood, AstraZeneca aspires to be the fastest-growing maker of cancer drugs, oncology chief Dave Fredrickson said at Europe?s biggest cancer conference on Friday (Sep 9).


https://www.shareinvestor.com/news/news ... 0medicines.

Ian.

Dod101
The full Lemon
Posts: 16629
Joined: October 10th, 2017, 11:33 am
Has thanked: 4343 times
Been thanked: 7534 times

Re: AstraZeneca PLC (AZN)

#529284

Postby Dod101 » September 12th, 2022, 8:01 am

idpickering wrote:AstraZeneca looks to more than double new cancer drugs by 2030.

The UK drugmaker has added 7 new cancer medicines since 2014 after chief executive officer Pascal Soriot made a risky bet on an oncology pipeline to revive growth and ward off a hostile takeover from Pfizer. Now, with blockbuster treatments for malignancies in the lungs, ovaries and blood, AstraZeneca aspires to be the fastest-growing maker of cancer drugs, oncology chief Dave Fredrickson said at Europe?s biggest cancer conference on Friday (Sep 9).


https://www.shareinvestor.com/news/news ... 0medicines.

Ian.


That's good news. It is about time/well past time that GSK was taking the same risks/making the same sort of long term investment strategy.

It is a pity that it is not so far being translated into a rather less modest dividend although I recognise that we have seen a good uplift in the share price. Investing for the future and all that.

Dod

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#529288

Postby idpickering » September 12th, 2022, 8:31 am

Dod101 wrote:
idpickering wrote:AstraZeneca looks to more than double new cancer drugs by 2030.

The UK drugmaker has added 7 new cancer medicines since 2014 after chief executive officer Pascal Soriot made a risky bet on an oncology pipeline to revive growth and ward off a hostile takeover from Pfizer. Now, with blockbuster treatments for malignancies in the lungs, ovaries and blood, AstraZeneca aspires to be the fastest-growing maker of cancer drugs, oncology chief Dave Fredrickson said at Europe?s biggest cancer conference on Friday (Sep 9).


https://www.shareinvestor.com/news/news ... 0medicines.

Ian.


That's good news. It is about time/well past time that GSK was taking the same risks/making the same sort of long term investment strategy.

It is a pity that it is not so far being translated into a rather less modest dividend although I recognise that we have seen a good uplift in the share price. Investing for the future and all that.

Dod


Thanks for your input Dod. As you may know AZN are my only holding in that sector nowadays. I’m v happy to hold, and have no intention of selling my AZN shares any time soon either.

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#530167

Postby idpickering » September 16th, 2022, 7:46 am

Nirsevimab recommended for approval in EU by CHMP.

AstraZeneca and Sanofi's Beyfortus (nirsevimab) has been recommended for marketing authorisation in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. If approved, Beyfortus would be the first and only single-dose passive immunisation for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Authority based its positive opinion on results from the Beyfortus clinical development programme, including the MELODY Phase III, MEDLEY Phase II/III, and Phase IIb trials.1-8


https://www.investegate.co.uk/astrazene ... 00047319Z/

Ian

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#530170

Postby idpickering » September 16th, 2022, 7:49 am

Two more from AZN today;

DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT.

https://www.investegate.co.uk/astrazene ... 10017314Z/

EVUSHELD POSITIVE CHMP OPINION IN EU.

https://www.investegate.co.uk/astrazene ... 05006823Z/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#530896

Postby idpickering » September 20th, 2022, 7:31 am

EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT.

AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.

The approval by the European Commission was based on results from the TACKLE Phase III COVID-19 treatment trial which showed one intramuscular (IM) dose of Evusheldprovided clinically and statistically significant protection against progression to severe COVID-19 or death from any cause compared to placebo. Evusheld treatment earlier in the disease course led to more favourable outcomes. TACKLE was conducted in non-hospitalised adults with mild-to-moderate COVID-19 who were symptomatic for seven days or less. 90% of trial participants were at high risk of progression to severe COVID-19 due to co-morbidities or age. Evusheld was generally well tolerated in the trial.1

Michel Goldman, M.D., Ph.D., Professor, Institute for Interdisciplinary Innovation in Healthcare, Université Libre de Bruxelles, and former Executive Director of the European Innovative Medicines Initiative, said: "Many people, including those who are immunocompromised, older adults and those with underlying health conditions, are at high risk of severe disease, hospitalisation and death if they become infected. Evusheld, delivered in a convenient intramuscular formulation, is now a much-needed new COVID-19 treatment option for these vulnerable populations."


https://www.investegate.co.uk/astrazene ... 00139500Z/

Ian

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#531169

Postby idpickering » September 21st, 2022, 7:11 am

Tezspire approved in the EU for the treatment of severe asthma.

AstraZeneca's Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.

The approval by the European Commission was based on results from the PATHFINDER clinical trial programme, which i ncluded the pivotal NAVIGATOR Phase III trial in which Tezspire demonstrated superiority across every primary and key secondary endpoint in patients with severe asthma, compared to placebo, when added to standard therapy.1 The approval follows the recommendation by The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency in July 2022.

Tezspire is the first and only biologic approved in Europe for severe asthma that acts at the top of the inflammatory cascade by blocking thymic stromal lymphopoietin (TSLP) , an epithelial cytokine .1-4Tezspire consistently and significantly reduced asthma exacerbations across the PATHWAY Phase II and the NAVIGATOR Phase III clinical trials, which included a broad population of severe asthma patients irrespective of key biomarkers, including blood eosinophil counts, allergic status and fractional exhaled nitric oxide (FeNO).1,2


https://www.investegate.co.uk/astrazene ... 00060635A/

Ian.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: AstraZeneca PLC (AZN)

#531411

Postby idpickering » September 22nd, 2022, 7:30 am

Lynparza approved in China for ovarian cancer.

AstraZeneca and MSD's Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD)-positive status .

In China, ovarian cancer is the third most common gynaecologic cancer, with a five-year survival rate of approximately 39%, largely because more than 70% of women are diagnosed with advanced disease (Stage III or IV).1,2 In 2020, there were over 55,000 new cases of ovarian cancer in China.3

The approval by China's National Medical Products Administration was based on an HRD-positive subgroup exploratory analysis of the PAOLA-1 Phase III trial which showed Lynparza plus bevacizumab demonstrated a substantial progression-free survival (PFS) improvement versus bevacizumab alone for patients with HRD-positive advanced ovarian cancer. During European Society for Medical Oncology Congress (ESMO) 2022, the final overall survival (OS) results were presented from the PAOLA-1 Phase III trial demonstrating that Lynparza plus bevacizumab provided a clinically meaningful improvement in overall survival in HRD-positive advanced ovarian cancer.


https://www.investegate.co.uk/astrazene ... 00142779A/

Ian.


Return to “Company Share news (LSE Main Market)”

Who is online

Users browsing this forum: Google Adsense [Bot] and 8 guests